March 6, 2021

Dr Reddy’s Laboratories will get USFDA nod for Xeglyze lotion, used for lice therapy

New Delhi: Drug main Dr Reddy’s Laboratories on Monday introduced approval from the US well being regulator for Xeglyze lotion, utilized in therapy of head lice infestation. In September 2015, Dr Reddy’s Laboratories had signed a commercialisation take care of Australia’s Hatchtech for the latter’s prescription head lice product Xeglyze Lotion.

Dr Reddy’s Laboratories mentioned it’s working to commercialise this product by way of companions.

In a regulatory submitting, Dr Reddy’s Laboratories introduced it has acquired “approval of Xeglyze (abametapir) lotion… by the US Meals and Drug Administration (USFDA)”.

The approval triggers the contractual pre-commercialisation milestone of USD 20 million (about Rs 149 crore) payable to Hatchtech Pty Ltd, the corporate added.

Xeglyze is indicated for the topical therapy of head lice infestation in sufferers 6 months of age and older.

Shares of Dr Reddy’s Laboratories had been buying and selling 0.95 per cent decrease at Rs 4,025 apiece on the BSE.